Pulmonology Medical News about Paclitaxel Lung Neoplasms

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Weekly paclitaxel and cisplatin in the treatment of elderly advanced non-small cell lung cancer
Chinese Journal of Lung Cancer, 10/26/09

LIANG Y et al. – The patients of advanced NSCLC more than 70 years old can tolerate weekly paclitaxel and cisplatin and can get benefit from this regiment.

Methods

50 chemotherapy-naïve patients with advanced NSCLC
> 70 years old
Administrated weekly paclitaxel and pisplatin regiment: PTX 80 mg/m2 intravenous infusion for 1 h, d1, d8 (given routine premedications before PTX), DDP 20 mg/m2 intravenous infusion, d1, d8, every 21 days

Results

50 patients were enrolled, and 48 patients were evaluable for response
ORR (overall response rate) 39.6%
Median survival time (MST) 14.8 months
1 year survival rate 58.3%
Most common adverse events were leucopenia (60%), anemia (62%), nausea and vomiting (30%), alopecia (100%)
No chemotherapy-related deaths

<< Previous
Prognostic value of symptom burden for overall survival in...

Next >>
Risk Factors for Mortality in Patients with Nosocomial...